Alyeska Investment Group L.P. Trims Stock Holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Alyeska Investment Group L.P. trimmed its holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) by 22.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,750,000 shares of the company’s stock after selling 500,000 shares during the period. Alyeska Investment Group L.P. owned about 1.69% of Unicycive Therapeutics worth $1,390,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Acuta Capital Partners LLC increased its stake in shares of Unicycive Therapeutics by 16.4% in the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company’s stock worth $1,829,000 after buying an additional 323,801 shares during the last quarter. Nantahala Capital Management LLC increased its position in shares of Unicycive Therapeutics by 268.5% in the 4th quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company’s stock worth $8,253,000 after purchasing an additional 7,571,636 shares during the last quarter. Northern Trust Corp lifted its position in shares of Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company’s stock worth $46,000 after purchasing an additional 34,183 shares during the last quarter. Vivo Capital LLC grew its stake in Unicycive Therapeutics by 123.0% in the fourth quarter. Vivo Capital LLC now owns 9,970,152 shares of the company’s stock worth $7,918,000 after purchasing an additional 5,500,000 shares in the last quarter. Finally, XTX Topco Ltd increased its holdings in Unicycive Therapeutics by 142.2% in the fourth quarter. XTX Topco Ltd now owns 171,463 shares of the company’s stock valued at $136,000 after buying an additional 100,679 shares during the last quarter. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

Unicycive Therapeutics Trading Down 6.5 %

NASDAQ:UNCY opened at $0.61 on Wednesday. The company has a 50-day moving average of $0.59 and a 200-day moving average of $0.60. Unicycive Therapeutics, Inc. has a twelve month low of $0.20 and a twelve month high of $1.20. The firm has a market cap of $72.51 million, a price-to-earnings ratio of -0.62 and a beta of 2.14.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, research analysts forecast that Unicycive Therapeutics, Inc. will post -0.23 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on UNCY shares. HC Wainwright reaffirmed a “buy” rating and set a $7.50 target price on shares of Unicycive Therapeutics in a report on Friday, April 11th. Guggenheim assumed coverage on shares of Unicycive Therapeutics in a report on Monday, April 21st. They issued a “buy” rating and a $6.00 price objective for the company.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.